An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity (Q56880144)

Albert D.M.E Osterhaus

11

0 references

Jaap Goudsmit

3

Jaap Goudsmit

0 references

Geert van Amerongen

9

Geert van Amerongen

0 references

Selma Yüksel

10

Selma Yüksel

0 references

author name string

Olga J.A.E Ophorst

1

0 references

Stefan Kostense

2

0 references

Sandra Verhaagh

5

0 references

Alexander Zakhartchouk

6

0 references

Marja van Meijer

7

0 references

Mieke Sprangers

8

0 references

Menzo J.E Havenga

Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.

12

0 references

language of work or name

English

0 references

publication date

August 2004

0 references

published in

Vaccine

0 references

volume

22

0 references

issue

23-24

0 references

page(s)

3035-3044

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Prior DNA vaccination does not interfere with the live-attenuated measles vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

The dendritic cell-specific chemokine, dendritic cell-derived CC chemokine 1, enhances protective cell-mediated immunity to murine malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Exploiting dendritic cells to improve vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Human PBMC-derived dendritic cells transduced with an adenovirus vectorinduce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Neutralizing antibodies against 33 human adenoviruses in normal children in Rome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Vaccination against measles: a neverending story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

One-round determination of seven leukocyte subsets in rhesus macaque blood by flow cytometry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Measles virus fusion protein- and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies by a FACS-measured immunofluorescence assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Phage-display selection of a human single-chain fv antibody highly specific for melanoma and breast cancer cells using a chemoenzymatically synthesized G(M3)-carbohydrate antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Phage-displayed mimotopes recognizing a biologically active anti-HIV-1 gp120 murine monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Simplified method to generate large quantities of dendritic cells suitable for clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Improved adenovirus vectors for infection of cardiovascular tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Genetic heterogeneity in response to adenovirus gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Macrophages and dendritic cells in normal and regenerating murine skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Immune responses to adenovirus and adeno-associated virus in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Hexon gene switch strategy for the generation of chimeric recombinant adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.011